SUPG Supergen, Inc. (MM)

SuperGen Announces New Executive Promotions And Appointments of Senior Officers DUBLIN, Calif., Oct. 30 /PRNewswire-FirstCall/ -- SuperGen, Inc. announced today that Edward Jacobs has been promoted to Chief Operating Officer. Mr. Jacobs has been SuperGen's Chief Business Officer and Chief Financial Officer. Audrey Jakubowski, Ph.D., has been promoted to Senior Vice President of Regulatory Affairs. In addition, the Company announced that Michael Molkentin has been appointed as Chief Financial Officer. These promotions and appointments are effective immediately. Both Mr. Jacobs and Dr. Jakubowski have had distinguished careers prior to joining SuperGen. Mr. Jacobs has held senior executive positions at ETEX, Sequus (Johnson & Johnson) and NeoRx after starting his pharmaceutical career at Johnson & Johnson and Adria Laboratories (Pfizer). Dr. Jakubowski has held a number of executive positions in international regulatory affairs companies Bristol Myers Research and Development (BMS), DuPont Merck Pharmaceuticals (BMS) and, most recently, SyStemix, Incorporated. Dr. Joseph Rubinfeld, Chairman and Chief Executive Officer of SuperGen, said, "It is my pleasure to announce the promotion of Ed Jacobs to Chief Operating Officer and Audrey Jakubowski to Senior Vice President of Regulatory Affairs. Ed has played a valuable role in many facets of the Company's development and is uniquely qualified to guide the day-to-day commercial operations of SuperGen going forward. In addition to Ed's operational duties, he will serve as the head of our European subsidiary, EuroGen, as he continues the effort of expanding the commercialization of our products. Audrey has been with us over five years and has been instrumental in guiding the overall regulatory strategy of our products while managing FDA interactions. Audrey will continue to be the executive force behind the planned upcoming submissions of Orathecin(TM) and Dacogen(TM) while making a great addition to our team of executive officers." Mr. Molkentin brings over fifteen years of financial leadership experience in a variety of industries, including biotechnology, to SuperGen. He most recently served as Interim Chief Financial Officer and Corporate Controller at Aradigm Corporation, where he participated in activities securing equity investments exceeding $123 million. Previously, Mr. Molkentin was Division Controller, Analytical Products Group, at Thermo Finnigan Corporation, (a subsidiary of Thermo Electron), where he was an active member in that organization's initial public offering (IPO). He also has served in various capacities at Vanstar Corporation, Republic Telecom Systems, Computer Automation and Rhode, Scripter and Associates, CPA. "Michael possesses a valuable combination of business savvy and a fundamental comprehension of the financial and administrative complexities involved in the biotechnology industry," said Dr. James Manuso, Chief Executive Officer -- Elect of SuperGen. "As we prepare to enter the next phase of our company's development, I am confident that Michael's management and financial experience will enable him to assist SuperGen in a variety of ways through a period of potential substantial growth and to develop and maintain an optimal capital structure." Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the development and commercialization of products intended to treat life-threatening diseases, particularly cancer. The Company's website can be reached at http://www.supergen.com/. This press release contains 'forward-looking' statements within the meanings of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. This press release contains forward-looking statements, including statements regarding the growth of our business, development of our products, the management of our business, and expectations regarding sales and profitability. The actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such factors may include, but are not limited to, risks and uncertainties related to obtaining regulatory approval of products and marketing and sales of our products. For other risks that may impact the Company's performance, please see the risk factors detailed in our quarterly report on Form 10-Q for the quarter ended June 30, 2003. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Contact: Tim Enns, Vice President, Investor Relations & Business Development, SuperGen, Inc., 800-353-1075, ext. 111 DATASOURCE: SuperGen Inc. CONTACT: Tim Enns, Vice President, Investor Relations & Business Development of SuperGen, Inc., +1-800-353-1075, ext. 111 Web site: http://www.supergen.com/

Copyright